EUROPA Trial European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003
EUROPA Trial 12, 218 low-risk patients with stable coronary artery disease Randomized, double-blind, placebo-controlled Perindopril § 8 mg/day § n=6, 110 Placebo § n= 6, 108 Endpoints (follow-up mean 3. 4 years): g g Primary – Composite of CV mortality, nonfatal MI, and cardiac arrest Secondary – Composite of total death, nonfatal MI, and cardiac arrest; heart failure; revascularization (PCI/CABG); and stroke www. Clinical trial results. org European Society of Cardiology 2003
EUROPA Trial CV death/non-fatal MI/ cardiac arrest CV Mortality p=0. 107 p=0. 0003 www. Clinical trial results. org European Society of Cardiology 2003
EUROPA Trial • Among patients with stable coronary artery disease, treatment with the ACE-I perindopril was associated with a reduction in the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest compared with placebo • ACE inhibitors have previously been shown to be effective in other patient populations, including heart failure, left ventricular dysfunction, and high-risk coronary artery disease patients • The present trial is the largest to show a benefit in stable, lowrisk CAD patients www. Clinical trial results. org